ZD-2767 is an antibody-directed enzyme prodrug therapy (ADEPT) agent. ZD-2767 is composed of the prodrug ZD2767P, carboxypeptidase G2 (CPG2), and the active drug ZD2767D. ZD-2767 achieves tumor-targeted drug delivery through an innovative ADEPT strategy, triggering apoptosis of cancer cells by causing irreparable DNA damage. ZD-2767 can be used for cancer research[1].